Preoperative hydronephrosis predicts adverse pathological features and postoperative survival in patients with high-grade upper tract urothelial carcinoma

Subo Qian 1, Chengcai Liang 2, Yu Ding 1, Chen Wang 1, Haibo Shen 1

1 Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; 2 Department of Gastric and Pancreatic Surgery, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China

ABSTRACT

Purpose: Epidemiological studies reported conflicting results about preoperative hydronephrosis in upper tract urothelial carcinoma (UTUC). This study aimed to investigate the association between preoperative hydronephrosis and pathologic features and oncologic outcomes in patients with UTUC treated by radical nephroureterectomy (RNU).

Materials and Methods: This was a retrospective, single-center cohort study of 377 patients treated by RNU without perioperative chemotherapy between January 2001 and December 2014. Logistic regression, Cox regression, and survival analyses were performed.

Results: Among the 226 patients with high-grade UTUC, 132 (58%) had preoperative hydronephrosis. Multivariable logistic regression revealed that hydronephrosis was independently associated with advanced pT stage (P=0.017) and lymph node or lymphovascular invasion (P=0.002). Median follow-up was 36 months (interquartile range: 20-48 months). The 3- and 5-year overall survival (OS) rates in patients with hydronephrosis were significantly lower than in those without hydronephrosis (both P <0.001). The 3- and 5-year cancer-specific survival (CSS) rates in patients with hydronephrosis were significantly lower than in those without hydronephrosis (both P=0.001). Hydronephrosis was independently associated with OS and CSS (P=0.001 and P=0.004, respectively). Among the 151 patients with low-grade UTUC, hydronephrosis was not associated with pathologic features and postoperative survival.

Conclusions: Preoperative hydronephrosis was significantly associated with adverse pathologic features and postoperative survival in patients with high-grade UTUC.

INTRODUCTION

Upper tract urothelial carcinoma (UTUC) is a rare malignancy, accounting for only 5%-10% of all urothelial carcinomas. UTUC arises from the urothelial lining of the urinary tract, from the renal calyces to the ureteral orifice, and the tumors of the renal pelvis and calyces are approximately twice as common as tumors of the ureters (1, 2). Although radical nephroureterectomy (RNU) is considered to be the preferred treatment for non-metastatic UTUC, disease progression often occurs and results in an unsatisfac-
tory outcome, particularly in tumors with advanced pathologic stages (3-5). In addition, contemporary data suggested that patients with muscle-invasive (pT2 or greater) or non-organ-confined (pT3-4 or lymph node involvement [LNI]) UTUC may benefit from neoadjuvant chemotherapy (6, 7) and lymphadenectomy (8, 9). Therefore, adopting an accurate prediction for the pathologic features of the disease before surgery is of clinical significance for therapeutic planning.

Currently, conventional preoperative strategies for evaluating the pathologic features of UTUC are limited to radiographic imaging and biopsy (10). Unfortunately, these methods are not reliable enough, with low sensitivity and specificity. Uncovering surrogate predictors of pathologic features in UTUC is of clinical significance.

Hydronephrosis is a common comorbidity in the diagnosis of UTUC and is the result of malignant obstruction in the upper urinary tract. Interestingly, recent evidence demonstrated an association between hydronephrosis and adverse pathologic features or prognosis in UTUC (11-14), but the prognostic role of hydronephrosis was not fully supported by other reports (15-17). In addition, the study by Chung et al. showed that hydronephrosis, as a surrogate for adverse pathologic and oncologic features, was found only in high-grade UTUC patients (18).

Therefore, an identification of the predictive potential of hydronephrosis in UTUC would be of clinical significance. We hypothesized that hydronephrosis was associated with the pathologic features and prognosis of UTUC and that the associations might be different between low- and high-grade UTUC. The present study aimed to investigate the potential of hydronephrosis as a surrogate associated factor of pathologic features as well as oncologic outcomes.

**SUBJECTS AND METHODS**

**Patients**

The patients pathologically diagnosed with upper tract tumors and who underwent RNU at the Department of Urology of our hospital between January 2001 and December 2014 were retrospectively reviewed. The patients with UTUC and dominant urothelial cell histology were included. UTUC was pathologically confirmed by preoperative biopsy under ureteroscopy or by intraoperative frozen section. The exclusion criteria were: (1) another malignant disease within 5 years; (2) underwent conservative surgery; (3) previous or concomitant radical cystectomy; (4) metastatic diseases; (5) perioperative chemotherapy; or (6) incomplete medical data. This study was approved by the Institutional Review Board of our hospital (No. XHEC-D-2018-057). Informed consent was waived by the committee because of the retrospective nature of the study.

**Surgery**

Patients underwent standard RNU (i.e., extraperitoneal dissection of the kidney with the entire ureter and adjacent segment of the bladder cuff). The hilar and regional lymph nodes adjacent to the ipsilateral great vessels were generally resected if palpable intraoperatively or if enlarged on preoperative axial imaging. All patients with previous or current non-muscle invasive bladder cancer (NMIBC) were treated by transurethral resection.

**Data collection**

All postoperative specimens were histologically confirmed to be urothelial carcinomas by two pathologists. Baseline characteristics including age, gender, tumor side, size, location, previous or current NMIBC, history of hypertension or diabetes mellitus, primary tumor stage (pT), primary tumor grade (2), LNI, lymphovascular invasion (LVI), preoperative hydronephrosis, and type of surgery (open or laparoscopic) were collected. Hydronephrosis was defined as the dilation of the calyx or renal pelvis (>1cm in the posterior-anterior plane), with or without renal parenchyma atrophy (19). Assessment of ipsilateral hydronephrosis was carried out according to the radiographic reports of upper urinary tract imaging, including computed tomography (CT), magnetic resonance imaging (MRI), intravenous pyelography, or renal ultrasonography. If more than one imaging modality was available for the same patient, preference was given to the CT report. Overall survival (OS) and cancer-specific survival (CSS) were estimated as the time from RNU to death.

**Follow-up**

All patients were generally followed every 3 months in the first year after surgery, then every 6
months from the second to the fifth years, and annually thereafter. Routine surveillance protocol included cystoscopy and blood/urine tests. Urinary cytology, elective bone scans, abdominal or chest CT, and MRI were performed when clinically indicated.

**Statistical Analysis**

All statistical analyses were performed using PASW Statistics 18.0 (IBM Corp., NY, USA). Continuous variables were presented as median (interquartile range [IQR]) and compared using the Mann-Whitney U test. Categorical variables were presented as frequency (percentage) and compared using the chi-square test. Survival was compared between patients with or without hydronephrosis using the Kaplan-Meier method and the log-rank test. Multivariable logistic regression and Cox proportional hazard models were used to evaluate the factors associated with pathologic parameters and survival. The variables that were significant in univariable analyses were entered into the multivariable analysis. P <0.05 was considered statistically significant.

**RESULTS**

A total of 377 patients were included in the study. The clinical characteristics of the patients are summarized in Table-1. The median follow-up was 36 months (IQR: 20-48 months). Low-grade cancers were detected in 151 (40.1%) patients, whereas 226 (59.9%) patients had high-grade cancers. In addition, 212 (56.2%) patients had preoperative hydronephrosis, including 60 (34.1%) out of 176 patients with renal pelvic tumor, 121 (80.7%) out of 150 patients with ureteral tumor, and 31 (60.8%) out of 51 patients with multifocal tumor.

Table-2 presented the clinical characteristics of patients with high-grade UTUC. The median age was 69 years (IQR: 58-76 years). Among the 226 patients with high-grade UTUC, 132 (58.4%) had preoperative hydronephrosis. The proportions of female patients, patients with ureteral tumors, advanced tumor stage (pT3-4), and LNI were significantly higher in the hydronephrosis group than in the non-hydronephrosis group (P=0.002, P <0.001, P <0.001, and P=0.003, respectively).

| Variable | Patients (n=377) |
|----------|-----------------|
| Age (years), median (interquartile range) | 70 (60-76) |
| Male, n (%) | 247 (65.5) |
| Tumor side, n (%) | |
| Left | 211 (56.0) |
| Right | 166 (44.0) |
| Tumor size (cm), n (%) | |
| ≤2.5 | 149 (39.5) |
| >2.5 | 228 (60.5) |
| Tumor location, n (%) | |
| Renal pelvis | 176 (46.7) |
| Ureter | 150 (39.8) |
| Multifocal | 51 (13.5) |
| Previous or current NMIBC, n (%) | 58 (15.4) |
| Hypertension or diabetes mellitus, n (%) | 170 (45.1) |
| Hydronephrosis, n (%) | 212 (56.2) |
| pT stage, n (%) | |
| pTa and pT1 | 149 (39.5) |
| pT2 | 87 (23.1) |
| pT3 | 125 (33.2) |
| pT4 | 16 (4.2) |
| Tumor grade, n (%) | |
| Low | 151 (40.1) |
| High | 226 (59.9) |
| Lymph node involvement, n (%) | |
| pN0/pNx | 350 (92.8) |
| pN1/2 | 27 (7.2) |
| Lymphovascular invasion, n (%) | 29 (7.7) |
| Type of surgery, n (%) | |
| Open | 254 (67.4) |
| Laparoscopic | 123 (32.6) |

NMIBC = non-muscle-invasive bladder cancer.
Table 2 - Clinical characteristics of patients with high-grade upper tract urothelial carcinoma.

| Variable                              | All (n=226) | No hydronephrosis (n=94) | Hydronephrosis (n=132) | P     |
|---------------------------------------|-------------|--------------------------|------------------------|-------|
| Age (years), median (IQR)             | 69 (58-76)  | 69 (58-75)               | 69 (59-76)             | 0.226 |
| Male, n (%)                           | 147 (65.0)  | 72 (76.6)                | 75 (56.8)              | 0.002 |
| Tumor side, n (%)                     |             |                          |                        | 0.337 |
| Left                                  | 131 (58.0)  | 58 (61.7)                | 73 (55.3)              |       |
| Right                                 | 95 (42.0)   | 36 (38.3)                | 59 (44.7)              |       |
| Tumor size (cm), n (%)                |             |                          |                        | 0.064 |
| ≤2.5                                  | 85 (37.6)   | 42 (44.7)                | 43 (32.6)              |       |
| >2.5                                  | 141 (62.4)  | 52 (55.3)                | 89 (67.4)              |       |
| Tumor location, n (%)                 |             |                          |                        | <0.001|
| Renal pelvis                          | 101 (44.7)  | 64 (68.1)                | 37 (28.0)              |       |
| Ureter                                | 95 (42.0)   | 18 (19.1)                | 77 (58.3)              |       |
| Multifocal                            | 30 (13.3)   | 12 (12.8)                | 18 (13.6)              |       |
| Previous or current NMIBC, n (%)      | 33 (14.6)   | 10 (10.6)                | 23 (17.4)              | 0.154 |
| Hypertension or diabetes mellitus, n (%)| 98 (43.3)  | 38 (40.4)                | 60 (45.5)              | 0.452 |
| pT stage, n (%)                       |             |                          |                        | <0.001|
| pT1 and pT1                           | 81 (35.8)   | 53 (56.4)                | 28 (21.2)              |       |
| pT2                                   | 42 (18.6)   | 7 (7.4)                  | 35 (26.5)              |       |
| pT3                                   | 90 (39.8)   | 31 (33.0)                | 59 (44.7)              |       |
| pT4                                   | 13 (5.7)    | 3 (3.2)                  | 10 (7.6)               |       |
| Lymph node involvement, n (%)         |             |                          |                        | 0.003 |
| pN0/pNx                               | 206 (91.2)  | 92 (97.9)                | 114 (86.4)             |       |
| pN1/2                                 | 20 (8.8)    | 2 (2.1)                  | 18 (13.6)              |       |
| Lymphovascular invasion, n (%)        | 22 (9.7)    | 6 (6.4)                  | 16 (12.1)              | 0.151 |
| Type of surgery, n (%)                |             |                          |                        | 0.488 |
| Open                                  | 143 (63.3)  | 57 (60.6)                | 86 (65.2)              |       |
| Laparoscopic                          | 83 (36.7)   | 37 (39.4)                | 46 (34.8)              |       |

IQR = interquartile range; NMIBC = non-muscle-invasive bladder cancer.
The multivariable logistic regression analyses showed that preoperative hydronephrosis was the only factor that was significantly associated with advanced pT stage in patients with high-grade UTUC (odds ratio [OR]=1.933, 95% confidence interval [CI]: 1.124-3.323, P=0.017). Preoperative hydronephrosis (OR=3.786, 95%CI: 1.617-8.867, P=0.002) and female gender (OR=0.400, 95%CI: 0.174-0.918, P=0.031) were independently associated with LNI or LVI (Table-3). In contrast, preoperative hydronephrosis was not significantly associated with an advanced pT stage (OR=1.038, 95%CI: 0.404-2.664, P=0.938) or LNI/LVI (OR=3.875, 95%CI: 0.788-19.048, P=0.095) in patients with low-grade UTUC. Only the tumor location (ureter vs. renal pelvis) was associated with an advanced pT stage (OR=0.055, 95%CI: 0.012-0.251, P <0.001). Only the tumor side (right vs. left) was associated with LNI/LVI (OR=0.196, 95%CI: 0.039-0.983, P=0.048).

During follow-up, in the high-grade group, 67 (29.6%) patients died, including 54 (23.9%) from UTUC. The 3- and 5-year OS rates in patients with hydronephrosis were significantly lower than in patients without hydronephrosis (63.9% and 39.2% vs. 83.5% and 68.9%, respectively; P <0.001) (Figure-1A). The 3- and 5-year CSS rates in patients with hydronephrosis were significantly lower than in patients without hydronephrosis (68.5% and 44.8% vs. 87.5% and 75%, respectively; P=0.001 (Figure-1B). The multivariable Cox regression analyses showed that age (hazard ratio [HR]=2.220, 95%CI: 1.346-3.662, P=0.002), hydronephrosis (HR=2.615, 95%CI: 1.468-4.658, P=0.001), and pT stage (pT1/pTa: HR=1; pT2: HR=4.169, 95%CI: 1.617-10.749, P=0.003; pT3: HR=4.954, 95%CI: 2.054-11.947, P<0.001; pT4: HR=7.073, 95%CI: 2.470-20.247, P<0.001) were independently associated with OS in high-grade disease. Age (HR=1.829, 95%CI: 1.060-3.156, P=0.030), hydronephrosis (HR=2.665, 95%CI: 1.361-5.221, P=0.004), pT stage (pT1/pTa: HR=1; pT2: HR=4.567, 95%CI: 1.459-14.295, P=0.009; pT3: HR=5.767, 95%CI: 1.992-16.697, P=0.001; pT4: HR=9.027, 95%CI: 2.661-30.621, P<0.001), and LNI (HR=2.239, 95%CI: 1.174-4.272, P=0.014) were independently associated with CSS in high-grade disease. In the low-grade cohort,

| Variable | High pT stage (pT3-4) | Lymph node involvement and/or lymphovascular invasion |
|----------|----------------------|------------------------------------------------------|
| Variable | OR (95% CI) | P | OR (95% CI) | P |
| Age | 0.758 (0.434-1.323) | 0.33 | 0.993 (0.468-2.105) | 0.985 |
| Gender (female vs. male) | 0.742 (0.412-1.335) | 0.319 | 0.400 (0.174-0.918) | 0.031 |
| Tumor side (right vs. left) | 1.139 (0.656-1.977) | 0.644 | 0.947 (0.448-2) | 0.886 |
| Tumor size (>2.5 vs. ≤2.5cm) | 1.573 (0.881-2.809) | 0.125 | 1.337 (0.593-3.017) | 0.484 |
| Tumor location | | | | |
| Ureter vs. renal pelvis | 1.007 (0.52-1.948) | 0.985 | 0.758 (0.321-1.791) | 0.528 |
| Multifocal vs. renal pelvis | 0.689 (0.284-1.673) | 0.410 | 0.366 (0.092-1.463) | 0.155 |
| Previous or current NMIBC (yes vs. no) | 1.229 (0.555-2.718) | 0.611 | 1.463 (0.535-4.001) | 0.458 |
| Hydronephrosis (yes vs. no) | 1.933 (1.124-3.323) | 0.017 | 3.786 (1.617-8.867) | 0.002 |
| Hypertension or diabetes mellitus (yes vs. no) | 1.264 (0.725-2.206) | 0.409 | 1.257 (0.595-2.655) | 0.548 |

NMIBC = non-muscle-invasive bladder cancer; OR = odds ratio; CI = confidence interval.

Table 3 - Multivariable logistic regression analysis for adverse pathologic features in patients with high-grade upper tract urothelial carcinoma.
hydronephrosis was not associated with postoperative survival (Figures 1C and D).

DISCUSSION

In accordance with previous studies (20-22), pathologic features such as pT, LNI, and LVI were confirmed to be the most crucial prognostic factors for UTUC in this study. In addition, we surprisingly found that hydronephrosis was significantly associated with an advanced pT stage (P=0.017) and LNI or LVI (P=0.002) in the high-grade UTUC group (Table-3), thereby demonstrating a surrogate associated factor of adverse pathologic features in UTUC.

In the present study, higher frequency of preoperative hydronephrosis was observed in patients with ureteral tumor than in those with pelvic tumor, both in high-grade (81.0% [77/95] vs. 36.6% [37/101]) and low-grade (80.0% [44/55] vs. 30.7% [23/75]) UTUC groups. Ureteral tumors might be faster to produce hydronephrosis than pelvic tumors. Indeed it has been reported that ureteral tumors were more likely to present hydronephrosis than renal pelvic tumors (13). Previous series also showed that ureteral tumors were associated with hydronephrosis, while

Figure 1 - Survival of patients with UTUC. (A) Overall survival in 226 patients with high-grade UTUC. (B) Cancer-specific survival in 226 patients with high-grade UTUC. (C) Overall survival in 151 patients with low-grade UTUC. (D) Cancer-specific survival in 151 patients with low-grade UTUC. CSS, cancer-specific survival; OS, overall survival; SE, standard error; UTUC, upper tract urothelial carcinoma.
pelvic tumors were not associated, except tumors of the pelviureteric junction (11, 15, 23, 24). Furthermore, the pattern of invasion of the surrounding tissues might affect the development of hydronephrosis. Pelvic tumors will invade into the renal parenchyma and the perinephric fat, but the likelihood of causing obstruction is small; on the other hand, ureteral tumors will directly invade the peri-ureter tissues, with a higher likelihood of compressing the ureter and obstructing urine flow (25).

Several studies attempted to investigate hydronephrosis in the prediction of pathologic features of cancers of the bladder and upper urinary tract. In patients with bladder cancer, Stimson et al. (26) reported that the presence of hydronephrosis before radical cystectomy was an independent predictor of adverse pathologic features (extravesical and node-positive disease). Small-sample studies reported a similar association, i.e., that hydronephrosis was significantly associated with muscle-invasive or non-organ-confined disease (11, 15). Afterward, Messer et al. (12) and Chung et al. (18) also reported this association, respectively, in larger multicenter studies of patients with high-grade UTUC. Nevertheless, conclusions from previous studies are often limited by the small samples (<150 patients). In addition, although the study by Messer et al. had a larger cohort, the lack of oncologic follow-up and the enrollment of patients who only underwent distal ureterectomy (9%) biased their results. Therefore, conducting a study on the prediction potential of hydronephrosis in UTUC was of clinical significance.

Different from most previous studies on the methodological point of view, the present study investigated the pathologic and prognostic relevance of hydronephrosis by subgroup analysis in a cohort of patients with high-grade UTUC. The association with muscle-invasive or non-organ-confined UTUC implies that hydronephrosis is likely caused by luminal obstruction as well as intramural invasion or extrinsic compression. In contrast, hydronephrosis may cause outward expansion and longitudinal thinning of the upper urinary tract, facilitating the seeding of cancer cells to regional or distant organs. Compared with high-grade disease, a low-grade disease is less poorly differentiated and less aggressive. Thus, the expanding pressure of hydronephrosis could less likely result in the spreading or aggressiveness of the disease in patients with low-grade UTUC. This indicates that analyzing all UTUCs together might dilute the pathologic and prognostic relevance of hydronephrosis. The subgroup analysis in the low-grade group demonstrated that hydronephrosis was not significantly associated with adverse pathologic features.

Notwithstanding, the prognostic relevance of hydronephrosis in UTUC after RNU still remains a controversial issue. In this study, according to the multivariable analysis, after incorporating only preoperative factors, hydronephrosis was found to be independently associated with OS and CSS (P=0.001 and P=0.004, respectively) in the high-grade cohort, which is in line with several previous studies. This is supported by available prognostic models and nomograms for UTUC; those that include hydronephrosis have a higher accuracy (27). Zhang et al. found that preoperative hydronephrosis was an independent predictor for CSS and progression-free survival (P=0.001 and P=0.007, respectively). Therefore, they reported that ureteral tumors showed a worse prognosis than renal pelvis tumors, which is likely due, at least in part, to more frequent hydronephrosis (13). Similarly, in another study, Ng et al. demonstrated that hydronephrosis was associated with worse CSS and metastasis-free survival when only preoperative variables were controlled (P=0.001 and P=0.004, respectively) (11). On the other hand, the studies conducted by Bozzini et al. (16) and Ito et al. (15) failed to show any difference in outcomes between the groups stratified by hydronephrosis. Thus, owing to the heterogeneity in methodology and based on the different criteria for hydronephrosis assessment and survival analysis, performing a comparative analysis among these studies would be fruitless. Nevertheless, we believe that preoperative hydronephrosis should be included in the evaluation of prognosis when it is taken into account as simple radiographic comorbidity and surrogate for poor pathologic features in patients with high-grade UTUC.

There are several mechanisms that might explain why hydronephrosis is an independent predictive factor for OS and CSS in the present study. First, Zhang et al. (13) reported that ureteral tumors were more likely to present hydronephrosis and less likely to have hematuria compared with renal pelvic tumors. Thus, it is reasonable to believe that ureteral
tumors are asymptomatic during the early stages because of incomplete obstruction, and presenting with hydronephrosis perhaps only during the late stages. The development of hydronephrosis might need some time after urinary tract obstruction resulting from the tumor. As a result, UTUC might progress during the development of hydronephrosis (13). Second, several studies reported that patients with hydronephrosis had a more advanced tumor stage than those without hydronephrosis (13, 14, 28). In addition, ureteral tumors were reported to be more likely to present with hydronephrosis and to have a worse prognosis than renal pelvic tumors, which could be attributed to the thin layer of surrounding ureteral adventitia containing an extensive plexus of blood vessels and lymphatic channels, making tumor invasion and metastasis easier (29, 30). The exact reasons why hydronephrosis is associated with an adverse prognosis in high-grade UTUC still need to be determined.

We must emphasize the limitations of this study. First and foremost, the retrospective nature of the study resulted in an accumulation of variability and inherent biases. Especially, the glomerular filtration rate could not be analyzed because of the amount of missing data. Second, the radical surgeries were performed by several surgeons, possibly resulting in some variations among cases. Third, although the CT or MRI images showed that all patients had renal pelvis or calyx dilation with proximal ureteral dilatation, we could not review the ultrasound images because our hospital does not retain ultrasound images. A previous study demonstrated that ultrasound and CT scans had different sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio for the diagnosis of hydronephrosis (31). This might be a limitation because some patients were diagnosed only by ultrasound. Fourth, it would provide greater information if we could evaluate an association between hydronephrosis and disease recurrence or progression. Fifth, patients who received perioperative chemotherapy were excluded because chemotherapy could influence survival, and to reduce the heterogeneity of the study population. On the other hand, we could not examine the influence of perioperative chemotherapy on the association between hydronephrosis and OS/CSS. Finally, because of the retrospective nature of the study, we were limited to the data available in the medical charts. Future studies could look at the combination of clinical markers combined with tissue-based molecular markers and inflammation scores to construct predictive and prognostic models for UTUC (32, 33). Overall, the surprising predictive value of preoperative hydronephrosis regarding pathology and prognosis of UTUC might be clinically significant.

CONCLUSIONS

In conclusion, preoperative hydronephrosis was associated with adverse pathologic features and postoperative survival in patients with high-grade UTUC. This finding suggests that hydronephrosis, as a promising prognostic factor, could be precious in properly guiding therapeutic approaches such as neoadjuvant chemotherapy and lymphadenectomy.

ABBREVIATIONS

CSS = cancer-specific survival
CI = confidence interval
CT = computed tomography
HR = hazard ratio
IQR = interquartile range
LNI = lymph node involvement
LVI = lymphovascular invasion
MRI = magnetic resonance imaging
NMIBC = non-muscle invasive bladder cancer
OR = odds ratio
OS = overall survival
pT = primary tumor stage
RNU = radical nephroureterectomy
UTUC = upper tract urothelial carcinoma

ACKNOWLEDGEMENTS

Subo Qian, Chengcai Liang, contributed equally to this work.

CONFLICT OF INTEREST

None declared.

REFERENCES

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29.
2. Rouprêt M. Reply to Yan Shiben and Wei Qiang’s Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015; 68:868-79. Eur Urol. 2016; 69:e51-2.

3. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009; 115:1224-33.

4. Inman BA, Tran VT, Fradet Y, Lacombe L. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer. 2009; 115:2853-62.

5. Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol. 2012; 61:818-25.

6. Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014; 66:329-41.

7. Cordier J, Sonpavde G, Stief CG, Tilki D. Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. World J Urol. 2013; 31:77-82.

8. Seisen T, Shariat SF, Cussenot O, Peyronnet B, Renard-Penna R, Colin P, et al. Contemporary role of lymph node dissection at the time of radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2017; 35:535-48.

9. Roscigno M, Cozzarini C, Bertini R, Scattoni V, Freschi M, Da Pozzo LF, et al. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. Eur Urol. 2008; 53:794-802.

10. Margulis V, Youssif RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, et al. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. J Urol. 2010; 184:453-8.

11. Ng CK, Shariat SF, Lucas SM, Bagrodia A, Lotan Y, Scherr DS, et al. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? Urol Oncol. 2011; 29:27-32.

12. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, et al. Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. Urol Oncol. 2013; 31:904-8.

13. Zhang X, Zhu Z, Zhong S, Xu T, Shen Z. Ureteral tumours showing a worse prognosis than renal pelvis tumours may be attributed to ureteral tumours more likely to have hydronephrosis and less likely to have haematuria. World J Urol. 2013; 31:155-60.

14. Cho KS, Hong SJ, Cho NH, Choi YD. Grade of hydronephrosis and tumor size as preoperative prognostic factors in urothelial transitional cell carcinoma. Urol. 2007; 70:662-6.

15. Ito Y, Kikuchi E, Tanaka N, Miyajima A, Mikami S, Jinzaki M, et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol. 2011; 185:1621-6.

16. Bozzini G, Nison L, Colin P, Ouzzane A, Yates DR, Audenet F, et al. Influence of preoperative hydronephrosis on the outcome of urothelial carcinoma of the upper urinary tract after nephroureterectomy: the results from a multi-institutional French cohort. World J Urol. 2013; 31:83-91.

17. Favaretto RL, Shariat SF, Savage C, Godoy G, Chade DC, Kaag M, et al. Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. BJU Int. 2012; 109:77-82.

18. Chung PH, Krabbe LM, Darwish OM, Westeman ME, Bagrodia A, Gayed BA, et al. Degree of hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract. Urol Oncol. 2014; 32:981-8.

19. Licurse A, Kim MC, Dziura J, Forman HP, Formica RN, Makarov DV, et al. Renal ultrasonography in the evaluation of acute kidney injury: developing a risk stratification framework. Arch Intern Med. 2010; 170:1900-7.

20. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol. 2012; 62:100-14.

21. Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015; 41:310-9.

22. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol. 2010; 57:1064-71.

23. Kini H, Sridevi HB, Suresh PK, Gunp LP, Bhat S, Kini JR. Spectrum of Lesions Affecting the Renal Pelvis and Pelviureteric Junction: A 13-Year Retrospective Analysis. J Clin Diagn Res. 2016; 10:EC01-4.
24. Brien JC, Shariat SF, Herman MP, Ng CK, Scherr DS, Scoll B, et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol. 2010; 184:69-73.
25. Luo HL, Kang CH, Chen YT, Chuang YC, Lee WC, Cheng YT, et al. Severity of hydronephrosis correlates with tumour invasiveness and urinary bladder recurrence of ureteric cancer. BJU Int. 2013; 112:489-94.
26. Stimson CJ, Cookson MS, Barocas DA, Clark PE, Humphrey JE, Patel SG, et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol. 2010; 183:1732-7.
27. Mbeutcha A, Mathieu R, Rouprêt M, Gust KM, Briganti A, Karakiewicz PI, et al. Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. Transl Androl Urol. 2016; 5:720-34.
28. Chung HJ, Chen KK, Lin AT, Chang YH, Wu HH, Hsu TH, et al. Is renal function at the tumor side a prognostic factor in ureteral transitional cell carcinoma? Urol Int. 1997; 59:166-9.
29. Ouzzane A, Colin P, Xylinas E, Pignot G, Ariane MM, Saint F, et al. Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol. 2011; 60:1258-65.
30. Park J, Ha SH, Min GE, Song C, Hong B, Hong JH, et al. The protective role of renal parenchyma as a barrier to local tumor spread of upper tract transitional cell carcinoma and its impact on patient survival. J Urol. 2009; 182:894-9.
31. Pathan SA, Mitra B, Mirza S, Momin U, Ahmed Z, Andraous LG, et al. Emergency Physician Interpretation of Point-of-care Ultrasound for Identifying and Grading of Hydronephrosis in Renal Colic Compared with Consensus Interpretation by Emergency Radiologists. Acad Emerg Med. 2018; 25:1129-1137.
32. Favaretto RL, Zequi SC, Oliveira RAR, Santana T, Costa WH, Cunha I W, et al. Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications. Int Braz J Urol. 2018; 44:22-37.
33. Suyama T, Kanbe S, Maegawa M, Shimizu H, Nakajima K. Prognostic significance of inflammation-based prognostic scoring in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol. 2019; 45:541-8.

Correspondence address:
Haibo Shen, MD
Department of Urology,
Xinhua Hospital, School of Medicine,
Shanghai Jiao Tong University,
1665 Kongjiang Road, Yangpu,
Shanghai 200092, China
Fax: + 86-021-25078080
E-mail: shenhaibo@xinhuamed.com.cn